Ironwood Pharmaceuticals (IRWD) Non-Current Deffered Revenue (2010 - 2018)

Ironwood Pharmaceuticals has disclosed Non-Current Deffered Revenue across 9 years of filings, most recently posting $6.3 million for Q4 2018.

• In Q4 2018, Non-Current Deffered Revenue rose 15.76% year-over-year to $6.3 million; the TTM figure through Dec 2018 stood at $6.3 million (up 15.76% YoY), while the FY2018 annual figure was $6.3 million, up 15.76% from the prior year.
• Non-Current Deffered Revenue came in at $6.3 million for Q4 2018 at Ironwood Pharmaceuticals, up from $6.1 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $10.5 million in Q4 2014 to a low of $557000.0 in Q4 2016.
• Average Non-Current Deffered Revenue over 5 years is $6.3 million, with a median of $6.2 million recorded in 2018.
• Year-over-year, Non-Current Deffered Revenue slumped 91.29% in 2016 and surged 878.28% in 2017.
• Over 5 years, Non-Current Deffered Revenue stood at $10.5 million in 2014, then plunged by 39.22% to $6.4 million in 2015, then tumbled by 91.29% to $557000.0 in 2016, then surged by 878.28% to $5.4 million in 2017, then climbed by 15.76% to $6.3 million in 2018.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $6.3 million in Q4 2018, $6.1 million in Q3 2018, and $6.1 million in Q2 2018.